| Anti-PD1 Monoclonal Antibody studied in …STUDIED_INderived35 of 35show fewer |
|---|
| → studied in | NCT06470971Phase 2 · recruiting Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial · 35 trials list this drug (19 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07830355Phase 2 · not yet recruiting Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph Nodes · 35 trials list this drug (19 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05254899Phase 2 · completed A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102) · 35 trials list this drug (19 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06425926Phase 1/Phase 2 · recruiting Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors · 35 trials list this drug (19 active) | — | — | Solid Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05774275Phase 1/Phase 2 · recruiting The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma · 35 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07365592Phase 1/Phase 2 · recruiting Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC · 35 trials list this drug (19 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05182957Phase 2 · recruiting Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma · 35 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07288034Phase 2 · recruiting Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial · 35 trials list this drug (19 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07090148Phase 1 · recruiting Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC · 35 trials list this drug (19 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03983057Phase 2 · completed Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer · 35 trials list this drug (19 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04146298Phase 1/Phase 2 · recruiting Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer · 35 trials list this drug (19 active) | — | — | Malignant Neoplasm,Malignant Pancreatic Neoplasm,Pancreatic Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05941507Phase 1/Phase 2 · recruiting A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors · 35 trials list this drug (19 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06255223Phase 2 · recruiting A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy · 35 trials list this drug (19 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06547957Phase 1 · active not recruiting A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors · 35 trials list this drug (19 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06556199Phase 1/Phase 2 · recruiting A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma · 35 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06728657Phase 2 · suspended Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma · 35 trials list this drug (19 active) | — | — | Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06603844Phase 1/Phase 2 · recruiting First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. · 35 trials list this drug (19 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05713994recruiting Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma · 35 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05522582Phase 2 · active not recruiting Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors · 35 trials list this drug (19 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06349044NA · unknown A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies. · 35 trials list this drug (19 active) | — | — | Biliary Tract Carcinoma,Hepatocellular Carcinoma,Colorectal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05987345NA · unknown Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer · 35 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05717738unknown Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma · 35 trials list this drug (19 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06298123completed Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling · 35 trials list this drug (19 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06170710Phase 2 · recruiting Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC · 35 trials list this drug (19 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06121700Phase 2 · recruiting Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer · 35 trials list this drug (19 active) | — | — | Malignant Neoplasm,Gastric Neoplasm,Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05307198Phase 2 · unknown Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC · 35 trials list this drug (19 active) | — | — | Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05699811Phase 1/Phase 2 · recruiting IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors · 35 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05556200Phase 2 · unknown A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs · 35 trials list this drug (19 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05684211Phase 2 · unknown A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer · 35 trials list this drug (19 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05429684Phase 3 · unknown Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer · 35 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05149170Phase 2 · unknown Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL · 35 trials list this drug (19 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04928365Phase 2 · unknown Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy · 35 trials list this drug (19 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03704246Phase 2 · unknown Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors · 35 trials list this drug (19 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04676789Phase 2 · unknown Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL · 35 trials list this drug (19 active) | — | — | Extranodal NK-/T-Cell Lymphoma, Nasal Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04096690Phase 2 · unknown Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma · 35 trials list this drug (19 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |